Evista, also called raloxifene, is a medication that's used to reduce the risk of invasive breast cancer in post-menopausal women. It's also used to reduce the risk of spinal fractures related to ...
The STAR (Study of Tamoxifen and Raloxifene) trial, one of the largest breast cancer prevention trials ever conducted, showed that five years of Evista is as effective as tamoxifen in lowering risk of ...
Eli Lilly ($LLY) is staring down the barrel of its Evista patent expiration. And Tuesday, Teva Pharmaceutical Industries ($TEVA) won FDA approval to load the bullet ...
The aromatase inhibitor Femara is next up in new Evista study for breast cancer prevention. Landmark data from the STAR trial comparing tamoxifen and Evista® (raloxifene) showed Evista was comparable ...
INDIANAPOLIS, Aug. 9, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data on EVISTA® (raloxifene HCl tablets) therapy for more than three years was published online in ...
INDIANAPOLIS, Oct. 14 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that a total of 14 U.S. and global studies involving its ...
BOSTON (MarketWatch) -- Eli Lilly & Co. said Friday that the Food and Drug Administration has approved its osteoporosis drug Evista for the prevention of invasive breast cancer, but the drug will also ...
WASHINGTON—A federal appeals court on Wednesday affirmed a lower-court ruling that will block generic versions of Eli Lilly & Co.'s osteoporosis drug Evista from becoming available in the U.S. until ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results